Note: Descriptions are shown in the official language in which they were submitted.
Blakes Ref: 72571/00016
22995014.1
1
Polyunsaturated fatty acids for the treatment of diseases related to
cardiovascular,
metabolic and inflammatory disease areas
Priority
[0001] This application claims the benefit of priority of U.S.
= Provisional Patent Application No. 61/176,503. filed May 8, 2909.
Technical field
[0002] The present disclosure relates to lipid compounds of the
general formula (I):
R2
= R3
=
(I)
wherein
= RI is a Cio-C22 alkyl group, a Gio-C22 alkenyl group having 1-6 double
bonds, or a C10-C22 alkynyi group having 1-6 triple bonds;
= R2 and R3 are the same or different and may be chosen from a
hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an
alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an
= alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl
=
group, a carboxy group, an alkylsulfinyl group, an alkylsulfonyl group,
an amino group, and an alkylamino group, with the proviso that R2 and
R3 cannot both be a hydrogen atom: or
= R2 and R3 together form a cycloalkyl group, such as cyclopropane,
=
cyclobutane, cyclopentane, or cyclohexane,
= X is a carboxylic acid or a derivative thereof, such as, a carboxylic
ester, a carboxylic anhydride, carboxamide, phospholipid,
monoglyceride, diglyceride, or triglyceride;
_
CA 2760877 2017-03-20
.
.
-
Slakes Ref: 72571/00016
22995014.1
2
or a pharmaceutically acceptable salt, solvate, solvate of such salt or a
prodrug thereof.
[0003] In embodiments where R2 and R3 are different, the
compounds of formula (I) are capable of existing in stereoisomeric forms. It
will be understood that the invention encompasses all optical isomers of the
compounds of formula (I) and mixtures thereof.
[0004) The present disclosure also relates to pharmaceutical
compositions and lipid compositions comprising at least one compound of
formula (I). In addition, the present disclosure includes compounds of formula
(I) for use as medicaments or for use in therapy, such as for the treatment of
diseases related to the cardiovascular, metabolic, and inflammatory disease
areas.
Background =
[00051 Dietary polyunsaturated fatty acids (PUFAs) have effects on
=
diverse physiological processes impacting normal health and chronic
diseases, such as the regulation of plasma lipid levels, cardiovascular and
immune functions, insulin action, neuronal development and visual function.
[0006] Due to their limited stability in vivo and their lack of biological
specificity, PUFAs have not achieved widespread use as therapeutic agents.
Chemical modifications of the n-3 polyunsaturated fatty acids have been
performed by several research groups in order to change or increase their
effects.
[0007) For example, the hypolipidemic effects of
(4Z,72,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid (DHA) was
potentiated by introducing a substituent in the a- position of
(4Z,7Z,10Z,13Z,16Z,19Z)-ethyl docosa-4,7,10,13,16,19-hexaenoate (DHA
EE). (WO 2006/117664) It is reported that obese, high fat-fed mice treated
with alpha-substituted DHA derivatives prevented and reversed obesity and
=
. . .
. .
CA 2760877 2017-03-20
.
_
Slakes Ref. 72571/00016
22995014.1
3
glucose intolerance. (Rossmeisl, M., et at, Obesity (Silver Spring) 2009 Jan
15.)
[0008] Several research groups have prepared unsaturated fatty
acids with oxygen incorporated in the 8-position (Flock, S. et al., Acta
Chemica Scandinavica, (1999) 53: 436 and Pitt, MJ, et at., Synthesis, (1997)
1240-42).
[0009] A novel group of fatty acid derivatives combining an oxygen
atom in 8-position with a a-substituents represented by the general formula
(I)
has been developed. These novel fatty acids reduce lipid levels in a
dyslipidemic mice model to a greater extent than naturally occurring
polyunsaturated fatty acids.
Description of the Figures
[0010] Figure 1: Cholesterol and triglyceride levels in
AP0e3Leiden mice after administration of one embodiment of the present
disclosure and OmacorTm.
[0011] Figure 2: Cholesterol and triglyceride levels in
APOE*3Leiden.CETP mice after administration of one embodiment of the
present disclosure and fenOfibrate.
[0012] Figure 3: HDL levels in APOE*3Leiden.CETP mice after
administration of one embodiment of the present disclosure and fenofibrate.
Summary
[0013] One object of the present disclosure is to provide lipid
compounds having improved biological activity compared to naturally
occurring polyunsaturated fatty acids. This object may be achieved by a lipid
compound of formula (I)
R2
R1-0¨¨X
R3 (I).
CA 2760877 2017-03-20
. . . Blakes Ref: 72571/00016
22995014.1
4
[0014] For example, the present disclosure relates to compounds of
formula (I), wherein:
= R1 is a C10-C22 alkyl group, a C10-C22 alkenyl group having 1-6 double
bonds, or a Cio-C22 alkynyl group having 1-6 triple bonds;
= R2 and R3 are the same or different and may be chosen from a
hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an
alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an
alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl
group, a carboxy group, an alkylsulfinyl group, an alkylsulfonyl group,
an amino group, and an alkylamino group, with the provisio that R2
and R3 cannot both be a hydrogen atom; or
= R2 and R3 together can form a cycloalkyl group, such as cyclopropane,
cyclobutane, cyclopentane, or cyclohexane;
= X is a carboxylic acid or a derivative thereof, such as, a carboxylic
ester, a carboxylic anhydride , a carboxamide, a phospholipid, or a
triglyceride;
or a pharmaceutically acceptable salt, solvate, solvate of such salt or a
prodrug thereof.
[0015] In at least one embodiment, the alkyl group may be chosen
from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, and n-hexyl. The
alkenyl group may be chosen from allyl, 2-butenyl, and 3-hexenyl. The
alkynyl group may be chosen from propargyl, 2-butynyl, and 3-hexynyl. The
halogen atom may be chosen from fluorine, chlorine, bromine, and iodine.
The alkoxy group may be chosen from methoxy, ethoxy, propoxy, isopropoxy,
sec-butoxy, phenoxy, benzyloxy, OCH2CF3, and OCH2CH2OCH3. The
acyloxy group may be chosen from acetoxy, propionoxy, and butyroxy. The
aryl group is a phenyl group. The alkylthio group may be chosen from
methylthio, ethylthio, isopropyithio, and phenytfhio. The aikoxycarbonyl group
may be chosen from methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, and
butonTarbonyl. The alkylsulfinyl group may be chosen from methanesulfinyl,
=
. . . .
CA 2760877 2017-03-20
. . . . .
Makes Ret 72571/00016
22995014.1
ethanesulfinyl, and isopropanesulfinyl. The alkylsulfonyl group may be
chosen from methanesulfonyl, ethanesulfonyl, and isopropanesulfonyl. The
alkylamino group may be chosen from methylamlno, dimethylamino,
ethylamino, and diethylamino. The carboxylate group may be chosen from
ethyl carboxylate, methyl carboxylate, n-propyl carboxylate, isopropyl
carboxylate, n-butyl carboxylate, sec-butyl carboxylate, and n-hexyl
carboxylate. The carboxamide group may be chosen from carboxamides,
such as N-methyl carboxamide, N,N-dimethyl carboxamicle, N-cthyl
carboxamide and N,N-diethyl carboxamide.
[0016] In at least one embodiment of the invention, one of the
substituents R2 and R3 of the compound of formula (I) is hydrogen and the
other one is chosen from a hydroxy group, an alkyl group, a halogen atom,
an alkoxy group, an acyloiy group, an acyl group, an alkenyl group, an
alkynyt group, an aryl group, an alkylthio group, an alkoxycarbonyl group, a
carboxy group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group,
and an alkylamino group.
(0017] In another embodiment of the invention, the substituents R2
and Ft3 of the compound of formula (I) are the same or different and may be
chosen from a hydroxy group, an alkyl group, a halogen atom, an alkoxy
group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group,
an aryl group, an alkylthio group, an alkoxycarbonyl group, a carboxy group,
an alkylsulfinyl group, an alkylsulfonyl group, an amino group. For example,
R2 and R3may be chosen from methyl, ethyl, n-propyl, or isopropyl.
[0018] When derived or prepared from a polyunsaturated fatty acid,
R1 is typically a Cio-C22 alkenyl group with 3-6 double bonds, e.g. 3-6
methylene interrupted double bonds in Z configuration. For example, R1 may
be chosen from:
= a Ci5 alkenyl with 4 methylene interrupted double bonds in Z-
configuration,
=
. . . . . = == == = = = =
CA 2760877 2017-03-20
Blakes Ref: 72571/00016
22995014.1
6
= a Cie alkenyl with 3-5 double bonds, e.g. a C18 alkenyl with 5
methylene interrupted double bonds in Z configuration,
= a C20 alkenyl with 5 methylene interrupted double bonds in Z-
configuration, or
= a C22 alkenyl with 6 methylene interrupted double bonds in Z-
configuration.
[0019] Furthermore, Ri may be a C10-C22 alkynyl group, e.g. a CIEs-
C22 alkynyl with 1-6 triple bonds.
[0020] The present disclosure also relates to salts of the compound
of formula (I). Such salts may be represented by
R2
R1-0--C-X
R,
wherein X is COO", and Z" may be NH4, a metal ion such as Li', Na", or IC, a
protonated primary amine such as fert-butyl ammonium, (3s,5s,7s)-
adamantan-1-ammonium, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-
ammonium or a protonated aminopyridine (e.g., pyridine-2-ammonium), a
protonated secondary amine such as diethylammonium, 2,3,4,5,6-
pentahydroxy-N-methylhexan-1-ammonium, N-ethylnaphthalen-1-ammonium,
a protonated tertiary amine such as 4-methylmorpholin-4-ium, a protonated
guanidine such as amino((4-amino-'l-carboxybutyl)amino)methaniminium or a
protonated heterocycle such as 1H-imidazol-3-ium,
or by
=
=
. . . . . .
CA 2760877 2017-03-20
Blakes Ref: 72571/00016
22995014.1
7
R2
2
wherein X = COCY, and Z2* may be Mg2+ or Ca2+, or a diprotonated diamine
such as ethane-1,2-diammonium or piperazine-1,4-diium.
Another representative salt is
n-
R2
wherein X is COO', and Z" is protonated Chitosan:
/ OH OH
\ HO
NH3+
0 Ho
NH2
10021] Furthermore, the present disclosure relates to compounds of
formula (I), wherein X is a carboxylic acid in the form of a phospholipid.
Such
compounds may be represented by the following formulas (II-IV),
0
R2 R3 a
0=P-0
I \
W
=
CA 2760877 2017-03-20
Blakes Ref: 72571/00016
22995014.1
wherein W is:
NH2
0 OH
or
40 01-1
and
Rce 0
R2 R2
04__O\
W 014
wherein W is:
CA 2760877 2017-03-20
Blakes Ref: 72571/00016
22995014.1
9
or
01-1
OH
HO OH
OH
and
R3 R2
0-=--P---0
=
I \
0' W (IV)
wherein W is:
CA 2760877 2017-03-20
. - . . .
Blakes Ret 72571/00016
22995014.1
I
OH
= NH2, or
= 40
[0022] Compounds of formula (I), wherein X is a carboxylic acid in
the form of a triglyceride, a 1,2-diglyceride, a 1,3 diglyceride, a 1-
monoglyceride and a 2-monoglyceride, are also included within the present
disclosure. These are hereinafter represented by the formulas (V), (VI),
(VII),
(VIII) and (IX), respectively.
CA 2760877 2017-03-20
Blakes Ref: 72571/00016
22995014.1
11
R3 R2
0
0 Rt
R2 R3
0
0
112
Ri (V)
R3 R2
R
Ri Cr
92 R3
0
HO (VI)
R2 R3
R3
0
R2
0
R1 (VII)
CA 2760877 2017-03-20
Blakes Ref. 72571/00016
22995014.1
12
Ri 0
R2 R3
HO OOH
RI 0
R2 R3 (IX)
=
= [0023] The compounds of formula (I) are capable of existing in
stereoisomeric forms. It will be understood that the invention encompasses all
optical isomers of the compounds of formula (I) and mixtures thereof. Hence,
compounds of formula (I) that exist as diastereomers, racemates, and
=
enantiomers are included within the scope of the present disclosure.
[0024] The present disclosure also relates to at least one lipid
compound according of formula (I) for use as a medicament.
[0025] In a further embodiment, the present disclosure provides a
food supplement, a food additive, or a nutraceutical preparation comprising a
lipid compound of formula (I).
[0026] Such a food supplement may be produced for administration
through any route of administration. For example, the food supplement may
be administered as a liquid nutritional or as a beverage.
100273 The food supplement may be in the form of a capsule, e.g. a
gelatin capsule, and the capsule may be flavoured.
[0028] In still a further embodiment, the present disclosure provides
a pharmaceutical composition comprising at least one compound of formula
. . _
CA 2760877 2017-03-20
Blakes Ret 72571/00016
22995014.1
13
(I), optionally together with one or more pharmaceutically acceptable carriers
or excipients.
[0029] The novel lipid compounds and compositions of the
disclosure may be formulated in conventional oral administration forms, e.g.
tablets, coated tablets, capsules, powders, granulates, solutions,
dispersions,
suspensions, syrups, emulsions, and sprays, using conventional excipients,
e.g. solvents, diluents, binders, sweeteners, aromas, pH modifiers, viscosity
modifiers, antioxidants, corn starch, lactose, glucose, microcrystalline
cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric
acid,
water, ethanol, glycerol, sorbitol, polyethylene glycol, Propylene glycol,
cetylstearyi alcohol, carboxymethylcellulose, or fatty substances, such as
hard
fat or suitable mixtures thereof. Conventional formulation techniques, well
=
known in the art, may be used to formulate the lipid compounds according to
the present disclosure.
[0030] The compositions may be administered by conventional
administration routes, for example, orally. The use of orally administrable
compositions, e.g. tablets, coated tablets, capsules, or syrups are included
within the scope of this disclosure. For example, in some embodiments, the
composition may be in the form of a gelatin capsule, a tablet, or a sachet.
[0031] A suitable daily dosage of the at least one compound
according to formula (I) may range from about 1 mg to about 3 g. For
example, in some embodiments, the daily dose ranges from about 1 mg to
about 10 g, from about 50 mg to about 1 g, from about 10 mg to about 2 g,
from about 50 mg to about 500 mg, from about 50 mg to about 200 mg, from
about 100 mg to about 1 g,. from about 100 mg to about 500 mg, or from
about 100 mg to about 250 mg.
[0032] The pharmaceutical composition according to the present
disclosure may be used as a medicament.
[0033] The present disclosure also relates to lipid compositions
comprising at least one lipid compound according to formula (I). Suitably, the
CA 2760877 2017-03-20
Blakes Ref: 72571/00016
22995014.1
14
lipid composition may comprise at least 60% by weight, or at least 80% by
weight of the at least one compound of formula (I).
[0034] The lipid composition may further comprise a
pharmaceutically acceptable antioxidant, e.g. tocopherol or 3-BHA.
[0035) Further, the present disclosure relates to a lipid composition
for use as a medicament.
[00361 Additionally, the present disclosure relates to the use of a lipid
compound according to formula (I) for use in:
= activation or modulation of at least one of the human peroxisome
proliferator-activated receptor (PPAR) isoforms a, y or 0, wherein said
compound e.g. is a pan-agonist or modulator,
= the prevention or treatment of an inflammatory condition,
= the prevention or treatment of rheumatoid arthritis,
= the prevention or treatment of inflammatory bowel disease,
= the prevention or treatment of metabolic syndrome,
= the prevention and/or treatment of a dyslipidemic condition, e.g.
hypertriglyceridemia (HTG),
= the prevention and/or treatment of elevated triglyceride levels, LDL
cholesterol levels, and/or VLDL cholesterol levels,
= the treatment and/or the prevention of obesity or an overweight
condition,
= the reduction of body weight and/or for preventing body weight gain,
= the treatment and/or the prevention of a fatty liver disease, e.g. non-
alcoholic fatty liver disease (NAFLD),
= the treatment and/or the prevention of an inflammatory disease or
condition,
= the treatment and/or the prevention of atherosclerosis,
= the treatment and/or the prevention of peripheral insulin resistance
and/or a diabetic condition,
= the treatment and/or prevention of type 2 diabetes, or
CA 2760877 2017-03-20
Blakes Ref: 72571/00016
22995014.1
= the reduction of plasma insulin, blood glucose and/or serum
triglycerides.
[0037] The present disclosure also relates to lipid compounds
according to formula (I) for the treatment of the above mentioned conditions,
and to methods for the treatment and/or prevention of the conditions listed
above, comprising administering to a mammal in need thereof a
pharmaceutically effective.amount of a compound according to formula (I).
[0038] In addition, the present disclosure encompasses methods for
manufacturing lipid compounds of formula (I). The raw material may e.g.
originate from a vegetable, a microbial and/or an animal source, such as a
marine fish oil. In at least one embodiment marine oil or a krill oil is used.
Detailed description
[0039] The present inventors have found that compounds of formula
(I) have remarkably good Pharmaceutical activity.
[0040] As used herein, the term "lipid compound" relates to fatty acid
analogues derived from e.g. saturated fatty acids, monounsaturated fatty
acids, polyunsaturated fatty acids and lipids comprising 1-6 triple bonds. It
is
to be understood that derived from includes preparation of the compounds of
formula (I) from fatty acids, such as saturated fatty acids, monounsaturated
fatty acids, polyunsaturated fatty acids and lipids comprising 1-6 triple
bonds.
Such fatty acids may occur naturally or be synthetic.
[0041] A "pharmaceutically effective amount" relates to an amount
that will lead to the desired pharmacological and/or therapeutic effects, i.e.
an
amount of the disclosed product which is effective to achieve its intended
purpose. While Individual patient needs may vary, determination of optimal
ranges for effective amounts of the disclosed product Is within the skill of
the
art. Generally, the dosage regimen for treating a condition with the disclosed
product of this invention is selected in accordance with a variety of factors,
including the type, age, weight, sex, diet and medical condition of the
patient.
=
-
CA 2760877 2017-03-20
-
Blakes Ref: 72671/00016
22995014.1
16
=
[0042] By "a pharmaceutical composition" is meant a lipid compound
according to the present disclosure in any form suitable to be used for a
medical purpose.
[0043] "Treatment" includes any therapeutic application that can
benefit a human or non-human mammal. Both human and veterinary
treatments are within the scope of the present disclosure. Treatment may be
in respect of an existing condition or it may be prophylactic, for example,
preventative.
[0044] Fatty acids are straight chain hydrocarbons possessing a
carboxyl (COON) group at one end (a) and (usually) a methyl group at the
other (w) end. In chemistry, the numbering of the carbon atoms starts from
the a end.
0
3 1
H 7. 10 13 16 19
[0045] The a carbon refers to the first carbon after the carbon that
attaches to the functional group, and the second carbon is the 33 carbon.
As used herein, the expression "methylene interrupted double bonds"
relates to the case when a methylene group (-CI-12-) is located between two
double bonds in a carbon chain of a lipid compound.
[0046] More particularly, the inventors have surprisingly found that
the following lipid compound categories A-D are particularly preferable.
Category A
= derived from saturated fatty acids
= R1 is a Clo-022 alkyl
Example
R1 =C4 =
. . . . . . . .
CA 2760877 2017-03-20
Makes Ref: 72571/00016
22995014.1
17
RrR2
Category B
= derived from monounsaturated fatty acids
= RI is a Cl0-C22 alkenyl having 1 double bond
Example ii:
R1:: C18
R3 R2
0 X
Example iii:
=
Ri = C14
0.x X
R3 R2
Category C:
= derived from polyunsaturated fatty acids
= RI is a C20 alkenyl having 5 double bonds
Example iv:
R1 rr. C20 with 6 methylene interrupted double bonds in Z-configuration
R3 R2
0 X
Category 0:
= derived from polyunsaturated fatty acids
CA 2760877 2017-03-20
Blakes Ref: 72571/00016
22995014.1
18
= R1 is a C22 alkenyl having 6 double bonds
Example v:
RI = C22 with 6 methylene interrupted double bonds in Z-configuration
R2 R3
Category E:
= derived from polyunsaturated fatty acids
= R, is a C18 alkenyl having 3 double bonds
Example vi:
Ri = Cis with 3 methylene interrupted double bonds in Z-configuration
R3 R2
0 X
Category F:
= derived from polyunsaturated fatty acids
= R1 is a C16 alkenyl having 4 double bonds
Example vii:
R1 = C15 with 4 methylene Interrupted double bonds in Z-configuration
Rx3 R2
('OX
Category G:
=
=
CA 2760877 2017-03-20
19
= derived from polyunsaturated fatty acids
= R, is a C18 alkenyl having 5 double bonds
Example viii:
R1 = C-8 with 5 methylene interrupted double bonds in Z-configuration
R3 R2
0 X
Category H:
= X is a carboxylic acid in the form of a triglyceride, diglyceride,
monoglyceride or phospholipid
Example ix:
X = a carboxylic acid in the form of a triglyceride
0 =
R2 R3
RI,
0 RI
0 R2 R3
0
OK0
R I
Ri R3
Example x:
X = a carboxylic acid in the form of a 2-monoglyceride
R2 R3
R1,0)ey0y^,
0
COH
Category I
=
CA 2760877 2017-03-20
Makes Ref: 72571/00016
= 22995014.1
20 =
= X is a carboxylate salt
Example xi:
( R2 R3
R1,0r0") X, n zn4
0
= n = 1 or 2
Category J
= derived from lipids comprising 1-6 triple bonds
= RI is a C10-C22 alkynyl
Example xii:
Ri = C14 with 1 triple bond
Ox X
R3 R2
[00471 The compounds of categories A-J above, where R2 and R3
are different, are capable of existing in stereoisomeric forms, i.e. all
optical
isomers of the compounds and mixtures thereof are encompassed. Hence,
the said Compounds may be present as diastereomers, racemates, and
enantiomers.
[0048] Specific examples of preferred lipid compounds according to
the present disclosure include:
=
CA 2760877 2017-03-20
Blakes Ref: 72571/00016
22995014.1
21
Category A:
0
0õA.OH
2-(Tetradecyloxy)butanoic acid (1)
Ri = C14H20, R2 = ethyl, R3= H and X = COOH
0
0o-A.OH
2-ethyl-2-(tetradecyloxy)butanoic acid (2)
R1= CI4H29, R2 = R3 = ethyl and X = COOH
0
0
.sfit's0H
2-(tetradecyloxy)propanoic acid (3)
Ri = C141129, R2 = methyl, R3= H and X = COOH
=
0
= 5<iLOH
2-methyl-2-(tetradecyloxy)propanoic acid (4)
R1= Ci4H29, R2= R3= methyl and X = COOH
0
o yl,OH
2-methoxy-2-(tetradecyloxy)acetic acid (5)
=
CA 2760877 2017-03-20
22
R1= C141129, R2 = methoxy, R3 = H and X = COOH
0
0.?t,OH
2-ethoxy-2-(tetradecytoxy)acetic acid (6)
Ri = G14H29, R2 = ethoxy, R3 = H and X = COOH
Category B:
0
Oy.
(Z)-2-(tetradec-6-en-1-yloxy)butanoic acid (7)
RI = C141-127, R2 = ethyl, R3 = H and X = COON
0
06k.OH
(Z)-2-ethyl-2-(tetradec-6-en-1-yloxy)butanoic acid (8)
R1 = Ci4H22, R2 = R3 = ethyl and X = COOH
0
OTIL,OH
(Z)-2-(tetradec-6-en-1-yloxy)propanoic acid (9)
RI = C14H27, R2 = methyl, R3 = Ft and X = COON
0
OxIL,OH
CA 2760877 2017-03-20
Blakes Ref: 72571/00016
22995014.1
23
=
(Z)-2-methy1-2-(tetradec-6-en-1-yloxy)propanoic acid (10)
R1= C14H27, R2 = R3= methyl and X = COOH
0
0,1)LOH
0
(Z)-2-methoxy-2-(tetradec:6-en-1-yloxy)acetic acid (11)
R1 = CI4H27, R2 = methoxy, R3 z.= H and X = COON
0
"T'lls'11
0 0
(Z)-2-ethoxy-2-(tetradec-6-.en-1-yloxy)acetic acid (12) =
R1= C14H27, R2 = ethoxy, R3 = H and X = COON
Category C:
- ¨ OX1rOH
- ¨ 0
21(5Z,82,112,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)butanoic acid
(13)
R1 = C201-131, R2 = ethyl, R3 = H and X = COON
¨ ¨ 0
2-ethyI-2-((5Z,8Z,11Z,14Z,172)-icosa-5,8,11,14,17-pentaen-1-yloxy)butanoic
acid (14)
R1 = C201-131, R2 = R3= ethyl and X = COOH
. . .
CA 2760877 2017-03-20
Blakes Ref: 72571/00016
22995014.1
24
¨ 0ji0}1
¨
2-((5Z,87,117,147,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)propanoic acid
(15)
R1 = C20113/, R2 = methyl, R3 = H and X = COOH
¨ 0
2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)-2-
methylpropanoic acid (16) '
RI = C201131, R2 = R3= methyl and X = COOH
¨ ¨ 0
2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)-2-methoxyacetic
acid (17)
Ri = C20H31, R2 = methoxy, R3 = H and X = COOH
LO
0
2-ethoxy-24(5Z,8Z.11Z,14Z17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)acetic
acid (18)
Ri = C201-131, R2 = ethoxy, R3 = H and X = COON
Category D:
CA 2760877 2017-03-20
. _ . . .
Makes Ref: 72571/00016
22995014.1
0
2-((4Z.7Z,10Z,13Z,16Z19Z)-docosa-4,7,10,13,16,19-hexaen-1-yloxy)butanoic
acid (19)
Ri = C22H33, R2 = ethyl, R3 = H and X = COOH
0
¨ OoKon
2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaen-1-yloxy)-2-
ethylbutanoic acid (20)
= C22H33. R2 = R3 = ethyl and X = COOK
0
¨ ¨ ¨
2-((4z,7Z110z,13Z,16Z,191)-docosa-4,7,10,13,16,19-hexaen-1-
= yloxy)propanolo acld (21)
RI = C22H33, R2 = methyl, R3 = 11 and X = COOK
0
0*L01I
2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaen-1-y1oxy)-2-
methylpropanoic acid (22)
= C22H33, R2 = R3 = methyl and X = COON
0
CA 2760877 2017-03-20
... . _
Blakes Ref: 72571/00016
22995014.1
26
24(42,7Z,10Z,13Z,162,19Z)-docosa-4,7,10,13,16,19-hexaen-1-yloxy)-2-
. methoxyacetic acid (23)
R1 = C22H33, R2 = methoxy, R3 = H and X = COOH
0
¨ 01,K,OH
=
2-((4Z,7Z,10Z,13Z,16Z,14Z)-docosa-4,7,10,13,16,19-hexaen-1-yloxy)-2-
ethoxyacetic acid (24)
Ri = C22H33, R2 = ethoxy, R3 = H and X = COOH
Category E:
0
2-((9Z,12Z,15Z)-octadeca-9,12,15-trien-1-yloxy)butanoic acid (25)
= C18H31, R2 = ethyl, R3 = H and X = COOH
=
=
OC)y H
0
2-ethy1-2-((9Z,12Z,15Z)-ociadeca-9,12,15-trien-1-yloxy)butanoic acid (26)
Ri = C181-131, R2 = R3= ethyl and X = COOH
o-ty
- 0
24(9Z,12Z,15Z)-octadeca-9,12,15-trien-1-yloxy)propanoic acid (27) =
R1 = C18H31, R2 = methyl, 1R3 = H and X = COON
CA 2760877 2017-03-20
_ . .
Blakes Ref: 72571/00016
2299501 4.1
27
=
0Y.,0H
¨ ¨ 0
2-methyl-24(9Z,122,15Z)-octadeca-9,12,15-trien-1-yloxy)propanoic acid (28)
Ri = C18H31, R2 = R3= methyl and X = COOH
0-1.y.OH
2-mathoxy-2-((9Z,12Z,15Z)-octadeca-9,12,15-trien-1-yloxy)acetic acid (29)
R1 = C181131, R2 = methoxy, R3 = H and X = COOH
(0
0,J)(01-i
¨ ¨ 0
2-ethoxy-2-((9Z,12Z,15Z)-octadeca-9,12,15-trien-1-yloxy)acetic acid (30)
R1 = Ci8H31, R2 = ethoxy, R3 = H and X = COOH
Category F:
¨ 0"ThrOH
¨ 0
2-((3Z,6Z,9Z,12Z)-pentadeca-3,6,9,12-tetraen-1-yloxy)butanoic acid (31)
= C15H23, R2 = ethyl, R3 = H and X = COOH
QirOff
0
- 0
=
. . . .
CA 2760877 2017-03-20
. .
Blakes Ref: 72571/00016
22995014.1
28
2-ethyl-2-((3Z,6Z,9Z,12Z)4Nantadeca-3,6,9,12-tetraen-1-yloxy)butanoic acid
(32)
Ri = C15H23, R2 = R3 = ethyl and X = COOH
¨
- ¨ 0
2-((3Z,6Z,9Z,12Z)-pentadeca-3,6,9,12-tetraen-1-yloxy)propanoic acid (33)
R1 = C15-123, R2 = methyl, R3 = H and X = COOH
¨ ¨
¨ 0
2-methy1-24(3Z,6Z,9Z,12Z)-pentadeca-3,6,9,12-tetraen-1-yloxy)propanoic
acid (34)
RI = CI5H23, R2 = R3= methyl and X -= COOH
¨ 0
2-methoxy-24(3Z,6Z,9Z,12Z)-pentadeca-3,6,9,12-tetraen-1-yloxy)acetc acid
(35)
R1 = C15H23, R2 = methoxy, R3 = H and X = COON
0
- ¨ 0õkrOH
¨ 0
2-ethoxy-24(32,6Z,9Z,12Z)-pentadeca-3,6,9,12-tetraen-1-yloxy)acetic acid
(36)
Ri = C151123, R2 = ethoxy, R3 H and X = COON
CA 2760877 2017-03-20
Blakes Ref: 72571/00016
22995014.1
29
Category G:
OH¨ ¨
¨ ¨ 0
2-((3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaen-1-yloxy)butanoic acid
(37)
R1 = C18F127, R2 = ethyl, R3 = H and X = COOH
. 0
2-ethyl-24(3Z,62,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaen-1-yloxy)butanoic
acid (38)
Ri C18/127, R2 = R3= ethyl and X = COOH
¨ ¨
0
¨ ¨ 0
2-((3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaen-1-yloxy)propanoic acid
(39)
R1= C181127, R2 = methyl, R3 = H and X = COOH
¨ OYsir
0
2-methyl-24(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaen-1-
yloxy)propanoic acid (40)
RI = C18H27, R2 = R3= methyl and X = COOH
=
CA 2760877 2017-03-20
Blakes Ref: 72571/00016
22995014.1
¨ ¨
0-1y 1-1
0
2-methoxy-2-((3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaen-1-
yloxy)acetic acid (41)
Ri = C181127, R2 methoxy, R3 = H and X = COOH
0
_
0
2-ethoxy-2-((3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaen-1-yloxy)acetic
acid (42)
R1 = C181127, R2 = ethoxy, R3 = H and X = COOH
Category H:
=
0
¨ ,-"s=-=:0)-y NCO".11X7
- ¨ 0
0
ONT,C:1 ¨
=
propane-1,2,3-triyltris(2-((52,8Z.11Z,14Z,17Z)-icosa-5,8,11 ,14,17-pentaen-1-
yloxy)butanoate) (43)
Ri = C201131, R2 = ethyl, R3 = H and X = a carboxylic acid in the form of a
triglyceride
- ¨ ¨ ;;Iy0r0H
¨ 0
OH
=
_
. . . .
CA 2760877 2017-03-20
Blakes Ref: 72571/00016
22995014.1
31
1,3-dihydroxypropan-2-y12-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-
pentaen-1-yloxy)butanoate (44)
R1 = C20F131, R2 = ethyl, R3 = H and X = a carboxyiic acid in the form of a 2-
monoglyceride
Category I:
¨ ¨ Na+
¨ 0
sodium 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-
yloxy)butanoate (45)
R, = C181-131, R2 = ethyl, R3 = H, X = COO' and Z+ is Na4.
= 0
potassium 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-
yioxy)butanoate (46).
R1 = C13H31, R2 = ethyl, R3 = H, X = COO' and Z+ is 1(4.
NI.
14+
¨ ¨ 0
ammonium 2-((5Z,8Z,11Z;14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-
yloxy)butanoate (47)
R1 = CI8H31, R2 = ethyl, R3 = H, X = COO' and r is NH4..
+143N
0
=
. . . . = . . .
CA 2760877 2017-03-20
Blakes Ref: 72571/00016
22995014.1
32
terf-butyl-ammonium 2-((5Z,8Z,112,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-
yloxy)butanoate (48).
Ri = Ci8F131, R2 = ethyl, R3 = H, X COO and r is tert-butyl ammonium.
OH
-H3N ________________________________________
1,3-dihydroxy-2-(hydroxymethyl)propan-2-aminium 2-((5Z,8Z,11Z,14Z,17Z)-
icosa-5,8,11,14,17-pentaen-1-yloxy)butanoate (49).
R1 = C18H31, R2 = ethyl, R3 = H, X = coo- and Z is 1,3-dihydroxy-2-
(hydroxymethyl)propan-2-ommonium.
o
0 mg2i
0
0
magnesium 2-((5Z18Z,11Z;14Z,17Z)-icosa-5,8,11,14,17-pentaen-l-
yloxy)butanoate (60).
R1 = C18H31, R2 = ethyl, R3 = H, X = coo- and Z2* is Mg2*.
o-o.
0
Ca2'
0
calcium 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-
yloxy)butanoate (51).
CA 2760877 2017-03-20
Blakes Ref: 72571/00016
22995014.1
33
Ri = C1811311 R= ethyl, R'3 = H, X = COO and Z2+ is Ca2+.
Category J:
0
OH
2-(tetradec-12-ynyloxy)butanoic acid (52)
Ri = C141123, R2 = ethyl, R3= H and X = COOH
0
OH
2-ethyl-.2-(tetradec-12-yn-1 -yloxy)butanoic acid (63)
Ri =C1411251 R2 = R3 Et ethyl and X = COOH
0
2-(tetradec-12-yn-1-yloxy)oropancic acid (54)
Ri = Cl4H2s, R2 = methyl, R3 = H and X = COOH
0
OH
2-methyl-2-(tetradec-12-yn-1-yloxy)propanoic acid (55)
Ri -7 C14H25, R2= R314 diethyl and X = COOH
0
OH
2-methoxy-2-(tetradec-12-ynyloxy)adetic acid (56)
CA 2760877 2017-03-20
. _
Blakes Ref: 72571/00016
22995014.1
34
RI = C141125, R2 = methoxy, R3 = H and X = COOH
0
01,AOH
eõ0
2-ethoxy-2-(tetradeo-12-yn-1-yloxy)acetic acid (57)
R1= C14H25, R2 = ethoxy, R3 = H and X = COON
[0049] Specific embodiment s of compounds according to the
present disclosure include the following.
General synthetic methods for the compounds described herein.
[0050] The compounds of general formula (I) can be prepared by the
following general procedures:
= Method I:
R1-0H
LGõ A _X Step) Rt" 0 X Step II Rr 0 X
+
R3 R2 R3 R2 R3 R2
(X) (XI)
Method II:
Step HI HO x Step IV
R1¨OH --P. Ri¨LG + ,s1-- A
K3 n2 R3 R2
(X) (XII)
Method III:
CA 2760877 2017-03-20
. . =
Blakes Ref: 72571/00016
22995014.1
HO x X Step V 0... X
Ri¨OH + R( )(
R3 R2 R3 112
(X) (XII)
[0051] The alcohols of formula (X) described in method I, II and III
may be prepared directly from the carboxylic esters of, for example, naturally
occurring fatty acids; e.g. alpha4inolenic acid, conjugated linoleic acid, or
eicosapentaenoic acid (EPA) by reduction with a reducing agent like lithium
aluminum hydride (LAH) or diisobultyl aluminum hydride (DIBAL-H) at -10 C
to 0 C. The alcohols can also be prepared by degradation of the
polyunsaturated fatty acids, such as EPA and DHA, as described by Holmeide
et al. (J.Chem. Soc., Perkin Trans. 1(2000) 2271.) In this case, one can
start with purified EPA or DHA, but it is also possible to start with fish oil
containing EPA and DHA.
[0052] Compounds of formula (XI) and (XII) are commercially
available, or they are known in the literature, or they are prepared by
standard
processes known in the art. The leaving group (LG) present in compounds of
formula (XI) may, for example, be mesylate, tosylate or a suitable halogen,
such as bromine. Other leaving groups will be apparent to the skilled artisan.
[0053] Using method I, the alcohols of formula (X) can react in a
substitution reaction with a compound of formula (XI) in the presence of base
such as an alkali metal hydroxide, for example NaOH in an appropriate
solvent system. Suitable solvent systems include a two-phase mixture of
toluene and water. In those cases where R2 and/or R3 present in the
compound of formula (XI) are hydrogen, an alkylation step may be added to
the sequence (Step II) in order to replace one or both of these hydrogen's
with
an alkyl group. Such alkylation may be performed by treating the product
from Step I with an alkyl group bearing a suitable leaving group, for example
a
halogen, such as bromine or iodine, or other leaving groups that will be
=
. .
CA 2760877 2017-03-20
Blakes Ref: 72571/00016
= 22995014.1
36
apparent to a person of ordinary skill in the art, in the presence of base,
such
as LDA in an appropriate solvent system.
[0054] Using method Il, the alcohols of formula (X) can be converted
= using functional group interconversion, by methods familiar to persons
skilled
in the art, to compounds where the terminal hydroxy group have been
transformed into a suitable leaving group (LG). Suitable leaving groups
include bromine, mesylate, and tosylate, or others that will be apparent to
one
of ordinary skill in the art. These compounds can be reacted further (step IV)
in a substitution reaction with the appropriately substituted hydroxy acetic
acid
derivatives (compounds of formula XII), in the presence of base in an
appropriate solvent system.
=
=
[0055] Using method Ill, the alcohol of formula (X) can react with the
appropriately substituted hydroxy acetic acid derivatives (compounds of
formula XII), under classic or non-classic Mitsunobu conditions, using
methods familiar to persons skilled in the art.
[0056] If the acid derivatives used are carboxylic esters, hydrolysis
can be performed to obtain the free fatty acids. An esterifying group such as
a methyl or an ethyl group may be removed, for example, by alkaline
hydrolysis using a base such as an alkali metal hydroxide, for example Li0H,
NaOH or KOH or by using an organic base, for example Et3N together with an
inorganic salt, for example Lie' in an appropriate solvent system. A tort-
butyl
group may be removed, for example, by treatment with an acid, for example
an organic acid such as trifluoroacetic acid or formic acid in an appropriate
solvent system. Suitable solvent systems include dichloromethane. An
arylmethylene group such as a benzyl group may be removed, for example.
by hydrogenation over a catalyst such as palladium-on-carbon In an
appropriate solvent system.
[0057) Salification of a carboxylic acid of formula (I) can be perfomed
by treating it with a suitable base in an appropriate solvent system. Removal
of the solvent will give the resulting salt.
. . CA 2760877 2017-03-20
_ . .
Blakes Ret. 72571/00016
22995014.1
37
[0058] The preparation of compounds of formula (I), according to
=
method I, II or Ill, may result in mixtures of stereoisomers. If required,
these
isomers may be separated by means of chiral resolving agents and/or by
chiral column chromatography through methods known to the person skilled in
the art.
=
Method IV.
[0059] The compounds of formula (I) wherein X is a carboxylic acid
derivative in the form of a phospholipid can be prepared through the following
processes.
HO
0 0
R.r X1LAG
R2 R3 R2 R3 0
GPC
Ri-O>j
R2 R3
= R2i30%,.= 9
R_0>?
0
0 E-)
[0060] Acylation of sn-glycero-3-phosphocholine (GPC) with an
activated fatty acid, such is fatty acid imidazolides, is a standard procedure
in
phosphatidylcholine synthesis. It is usually carried out in the presence of
DMS0 anion with DMSO as solvent. (Hermetter; Chemistry and Physics of
lipids, (1981) 28, 111.) Sn-Glycero-3-phosphocholine, as a cadmium (II)
adduct can also be reacted with the imidazolide activated fatty acid in the
. .
CA 2760877 2017-03-20
=
Blakes Ret 72571/00016
22995014.1
38
presence of DBU (1,8-diazabicyclo[5.4.0jundec-7-ene) to prepare the
phosphatidylcholine of the respective fatty acid. (International publication
number W0/2004/000854J Enzymatic
transphosphatidylation can effect
the transformation of phosphatidylcholine to phosphatidyletanolamine. (Wang
at al, J. Am. Chem. Soc., (1993) 115, 10487.)
[0061] Phospholipids may also be prepared by enzymatic
esterification and transesterification of phospholipids or enzymatic
transphosphatidylation of Phospholipids. (Hosokawa, J.Am. Oil Chem.Soc.
1995, 1287, Lilja-Hallberg, Biocatalysis, (1994) 195.)
Method V
[0062] The compounds of
formula (I) wherein X is a carboxylic acid
derivative in the form of a triglyceride can be prepared through the following
process. Excess of the fatty acid can be coupled to glycerol using
dimethylaminopyridine (DMAP) and 2-(1H-benzotriazol-1-y1)-N,N,K,N'-
tetramethyluroniumhexafluorophosphate (HBTU).
Method VI
[0063] The compounds of formula (I) wherein X is a carboxylic acid
derivative in the form of a diglyceride can be prepared by reaction of the
fatty
acid (2 equivalents) with glycerol (1 equivalent) in the presence of 1,3-
dicyclohexylcarbondiimide (DCC) and 4-dimethylaminopyridine (DMAP).
Method VII
[0064] The compounds of formula (I) wherein X is a carboxylic acid
derivative in the form of a monoglyceride can be prepared through the
following processes.
=
CA 2760877 2017-03-20
Blakes Ref: 72571/00016
22995014.1
39
0 OH
Rra'AAOH rcj<
OH
R3 R2
R3 R2 FR3 R2
OH Ole<
0
1,2-0-lsopropylldene-
0 0
sn-glycerol
[0065] Acylation of 1,2-0-isopropylidene-sn-glycerol with a fatty acid
using DCC and DMAP in chloroform gives a monodienoylglycerol.
Deprotection of the isopropylidene group can be done by treating the
protected glycerol with an acidic (HCI, acetic acid etc.). (O'Brian,
J.Org.Chem., (1996) 5914.)
[0066] There are several synthetic methods for the preparation of
monoglycerides with the fatty acid in 2-position. One method utilizes
esterification of the fatty acid with glycidol in the presence of 1-(3-
dimethylaminopropy1)-3-ethylcarbodiimidehydrochloride (EDC) and 4-
dimethylaminopyridine (DMAP) to produce a glyciciyl derivative. Treatment of
the glycidyl derivative with trifluoroacetic anhydride (TFAA) prior to trans-
esterification the monoglyceride is obtained (Parkkari et al, Bioorg.
Med.Chemlett. (2006) 2437.)
0
TFA A 0
R(5<ji,...0_7-000CF3
R(C5(10H R(.(3)(10"..-'s4
R3 R2 R3 R2 R3 R2 \-
000CF3
(glycidyl derivative)
PyridirielMe0H
Rc X5LO¨CH
R3 R2 OH
-=
CA 2760877 2017-03-20
. . .
=
Slakes Ref: 72571/00016
22995014.1
[0067] Further methods for the preparation of mono-, di- and tri-
glycerides of fatty acid derivatives are described in international
Publication
No. WO/2003/014074.
[0068] It is also possible to use enzymatic processes (lipase
reactions) for the transformation of a fatty acid to a mono-, di-, tri-
glyceride. A
1,3-regiospecific lipase from the fungus Mucor miehei can be used to produce
triglycerides or diglycerides from polyunsaturated fatty acids and glycerol. A
different lipase, the non-regiospecific yeast lipase from Candida antartica is
highly efficient in generating triglycerides from polyunsaturated fatty acids.
(Haraldsson, Pharmazie, (2000) 3.)
Preparation, characterization and biological testing of specific fatty acid
derivatives of formula (I)
Examples
10069] The disclosure will now be further described by the following
non-limiting examples, in which standard techniques known to the skilled
chemist and techniques analogous to those described in these examples may
be used where appropriate. Unless otherwise stated:
= evaporations were carried out by rotary evaporation in vacuo;
= all reactions were carried out at room temperature, typically in the
range between 18-25T with solvents of 1-IPLC grade under anhydrous
conditions;
= column chromatography was performed by the flash procedure on
silica gel 40-63 pm (Merck) or by an Armen Spotflash using the pre-
packed silica gel columns "MiniVarioRash", "SuperVarioFlash",
'SuperVarioPrep" or "EasyVarioPrep" (Merck);
= yields are given for illustration only and are not necessarily the
maximum attainable;
= the nuclear magnetic resonance (NMR) shift values were recorded on
a Bruker Avarice DPX 200 or 300 instrument, and the peak
_
CA 2760877 2017-03-20
_
Blakes Ref: 72571/00016
22995014.1
4'
multiplicities are Shown as follows: s, singlet; d, doublet; dd, double
doublet; t, triplet; q, quartet; p, pentet; m, multiplett; br, broad;
= the mass spectra were recorded with a LC/MS spectrometer.
Separation was performed using a Agilent 1100 series module on a
Eclipse XDB-C18 2.1 x 150 mm column with gradient elution. As eluent
were used a gradient of 5-95 % acetonitrile in buffers containing 0.01%
trifluoroacetic acid or 0.005% sodium formate. The mass spectra were
recorded with a G 1956 A mass spectrometer (electrospray, 3000 V)
switching positive and negative ionization mode.
Example 1:
Preparation of tert-butyl 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-
pentaen-1-yloxy)butanoate:
[0070] Tetrabutylammonium chloride (0.55 g, 1.98 mmol) was added
to a solution of (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-ol, (3.50 g,
12.1 mmol) in toluene (35 mL) at ambient temperature under nitrogen. An
aqueous solution of sodium hydroxide (50% (w/w), 11.7 mL) was added under
vigorous stirring at room temperature, followed by t-butyl 2-bromobutyrate
(5.41 g, 24.3 mmol). The resulting mixture was heated to 50 C and additional
t-butyl 2-bromobutyrate was added after 1.5 hours (2.70 g, 12.1 mmol), 3.5
hours (2.70 g, 12.1 mmol) and 4.5 hours (2.70g. 12.1 mmol) and stirred for
12 hours in total. After cooling to room temperature, ice water (25 mL) was
added and the resulting two phases were separated. The organic phase was
washed with a mixure of NaOH (5%) and brine, dried (MgSO4), filtered and
concentrated. The residue was purified by flash chromatography on silica gel
using increasingly polar mixtures of heptane and ethyl acetate (100:0 95:5)
as eluent. Concentration of the appropriate fractions afforded 1.87 g (36%
yield) of the title compound as an oil. 1H NMR (300 MHz, C0CI3): 6 0.85-
.
CA 2760877 2017-03-20
Blakes Ret. 72571(00016
22995014.1
42
1.10 (m, 6H), 1.35-1.54 (m, 11H), 1.53-1.87 (m, 4H), 1.96-2.26 (m, 4H),
2.70-3.02 (m, 8H), 3.31 (dt, 1H), 3.51-3.67 (m, 2H), 5.10-5.58 (m, 10H).
Example 2:
Preparation of 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-
pentaenyloxy)butanoic acid:
=W )YOH
0
tert-Butyl 24(5Z,82,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-
yloxy)butanoate (19.6g, 45.5 mmol) was dissolved in dichloro.methane (200
mL) and placed under nitrogen. Trifluoroacetic acid (50 mL) was added and
the reaction mixture was stirred at room temperature for one hour. Water was
added and the aqueous phase was extracted twice with dichloromethane. The
combined organic extract was washed with brine, dried (Na2SO4), filtered and
concentrated. The residue was subjected to flash chromatography on silica
gel using increasingly polar mixtures of heptane, ethyl acetate and formic
acid
(90:10:1 4 80:20:1) as eluent. Concentration of the appropriate fractions
afforded 12.1 g (71% yield) of the title compound as an oil. 'H-NMR (300
MHz, CDC13): 50.90-1.00 (m, 6H), '1.50 (m, 2H), 1.70 (m, 2H), 1.80 (m, 2H),
2.10 (m, 4H), 2.80-2.90 (m, 8H), 3.50 (m, 1H), 3.60 (m, 1H), 3.75 (t, 1H),
5.30-
5.50 (m, 10H); MS (electro spray): 373.2 [M-Hr.
Example 3:
Preparation of (48,5R)-34(S)-2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-
pentaenyloxy)butanoy1)-4-methy1-5-phenyloxazolidin-2-one and (48,5R)-
3-((R)-2-((5ZAZ,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoy1)-
4-methyl-5-phenyloxazolidin-2-one:
).-o otro
wcrAY.L? '-7-Cwc/(1)
=
. . . . . . .
.
CA 2760877 2017-03-20
Makes Ref: 72571/00016
22995014.1
43
[0071) DMAP (1.10 g, 8.90 mmol) and DCC (1.90g, 9.30 mmol)
were added to a mixture of 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-
pentaenyloxy)butanoic acid (3.20 g, 8.50 mmol) in dry dichloromethane (100
mL) held at 0 C under nitrogen. The resulting mixture was stirred at 0 C for
20
minutes. (4S,5R)-4-methyl-5-phenyloxazolidin-2-one (1.50 g, 8.50 mmol) was
added and the resulting turbid mixture was stirred at ambient temperature for
five days. The mixture was filtrated and concentrated under reduced pressure
=
to give a crude product containing the desired product as a mixture of two
diastereomers. The residue was purified by flash chromatography on silica
gel using 15% ethyl acetate in heptane as eluent. The two diastereomers
were separated and the appropriate fractions were concentrated. (4S,5R)-3-
((S)-2-((6Z,8Z,11Z,14Z,17Z)-icosa-5,8,11 .14,17-pentaenyloxy)butanoy1)-4-
methyl-5-phenyloxazolidin-2-one eluted first and was obtained in 1.1 g (40%
yield) as an oil. (46,5R)-34(R)-2-((5Z,82,11Z,14Z,17Z)-icosa-5,8.11,14,17-
pentaenyloxy)butanoy1)-4-methyl-5-phenyloxazolidin-2-one was obtained in
0.95 g (34% yield) as an oil.
(4S,5R)-3-((S)-2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-
pentaenyloxy)butanoy1)-4-methy1-5-phenyloxazolidin-2-one (El):
1H-NMR (300 MHz, CDCI3): 60.90 (d, 3H), 1.00 (t, 3H), 1.07 (t, 3H), 1.45-1.57
(m, 2H), 1,62-1.76 (m, 3H), 1.85-1.95 (m, 1H), 2.05-2.15 (m, 4H), 2.87 (m,
OH), 3.39(m, 1H), 3.57 (m, 1H), 4.85-4.92 (m, 2H), 5.30-5.45(m, 10H), 5.75
(d, 1H), 7.32 (m, 2H), 7.43 (m, 3H).
(48,5R)-3-((R)-2-((5Z,82,11Z,14Z,17Z)-icosa-5,8,11,14,17-
pentaenyloxy)butanoy1)-4-methy1-5-phenyloxazolidin-2-one (E2):
'H-NMR (300 MHz, CDC13): 60.98 (d, 3H), 0.99 (t, 3H), 1.08 (t, 3H), 1.40-1.52
(m, 2H), 1.55-1.75(m, 3H), 1.80-1.90(m, 1H), 2.05-2.15 (m, 4H), 2.84 (m,
OH), 3.39 (m, 1H), 3.56 (m, 1H), 4.79 (pent, 1H), 4.97 (dd, 1H), 5.30-5.45 (m,
10H), 5.71 (d, 1H), 7.33 (m, 2H), 7.43 (m, 3H).
. .
CA 2760877 2017-03-20
_ . . .
Blakes Ref: 72571/00016
22995014.1
44
Example 4: =
Preparation of (S)-24(52,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-
pentaenyloxy)butanoic acid:
[0072] Hydrogen peroxide (35% in water, 0.75 mL, 8.54 mmol) and
lithium hydroxide monohydrate (0.18 g, 4.27 mmol) was added to a solution of
(4S,5R)-34(S)-2-((5Z,8Z,1.1Z,14Z,17Z)-icosa-5,8,11,14,17-
pentaenyloxy)butanoy1)-4-methyl-5-phenyloxazolidin-2-one (1.10 g, 2.13
mmol) in tetrahydrofuran (12 mL) and water (4 mL) held at 0 C under
nitrogen. The reaction mixture was stirred at 0 C for 30 minutes. 10%
Na2S03 (aq) (30 mL) was added, the pH was adjusted to -2 with 2M HCI and
the mixture was extracted twice with heptane (30 mL). The combined organic
extract was dried (Na2SO4), filtered and concentrated. The residue was
subjected to flash chromatography on silica gel using increasingly polar
mixtures of heptane and ethyl acetate (98:8 1:1) as eluent. Concentration
of the appropriate fractions afforded 0.48 g (60 % yield) of the title
compound
as an oil. 1H-MAR (300 MHz, CDC13): 5 0.90-1.00 (m, 6H), 1.48 (m, 2H), 1.65
(m, 2H), 1.85 (m, 2H), 2.10(m, 4H), 2.80-2.90 (m, 8H), 3.55 (m, 1H), 3.60 (m,
1H), 3.88 (t, 1H), 5.35-5.45 (m, 10H): MS (electro spray): 373.3 [M-Hr: [ajD
+370 (c=0.104, ethanol)
Example 5:
Preparation of (R)-2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-
pentaenyloxy)butanoic acid:
¨
[0073] Hydrogen peroxide (35% in water, 0.65 mL, 7.37 mmol) and
lithium hydroxide monohydrate (0.15 g, 3.69 mmol) was added to a solution of
CA 2760877 2017-03-20
=
Blakes Ref: 72571/00016
22995014.1
(4S,5R)-3-((R)-2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-
pentaenyloxy)butanoy1)-4-methy1-5-phenyloxazolidin-2-one (0.95 g, 1.84
mmol) in tetrahydrofuran (12 mL) and water (4 mt.) held at 0 C under
nitrogen. The reaction mixture was stirred at 0 C for 30 minutes. 10%
Na2S03 (aq) (30 mL) was added, the pH was adjusted to ¨2 with 2M HCI and
the mixture was extracted twice with heptane (30 mL). The combined organic
extract was dried (Na2SO4), filtered and concentrated. The residue was
subjected to flash chromatography on silica gel using increasingly polar
mixtures of heptane and ethyl acetate (98:8 4 50:50) as eluent.
Concentration of the appropriate fractions afforded 0.19 g (29% yield) of the
title compound as an oil. 1H-NMR (300 MHz, CDC13): 5 0.90-1.00 (m, 6H),
1.48 (m, 2H), 1.65 (m, 2H), 1.86 (m, 2H), 2.10 (m, 4H), 2.80-2.90 (m, 8H),
3.55 (m, 1H), 3.60 (m, 1H), 3.88 (t, 1H), 5.35-5.45 (m, 101-1); MS (electro
spray): 373,3 [M-FIT; [a]o -31 (c=0.088, ethanol)
Example 6:
Preparation of tert-butyl 2-((5Z,8Z,112,14Z,17Z)-lcosa-5,8,11,14,17-
pentaenytoxy)propanoate:
o'LeNi"
[0074] A mixture of (5Z,8Z,11Z,14Z,17Z)-lcosa-5,8,11,14,17-
pentaen-1-ol, (1.00 g, 3.47 mmol), tetrabutylammonium chloride (0.24 g, 0.87
mmol) and t-butyl rx-bromo propionate (3.62 g, 17.3 mmol) was dssolved in
toluene (36 mL) and placed under nitrogen. An aqueous solution of sodium
hydroxide (50%, 8 mL) was added slowly under vigorous stirring and the
resulting mixture was stirred at ambient temperature for twenty hours. Water
. was added and the mixture was extracted three times with ether. The
combined organic extract was washed with brine, dried (Na2SO4), filtered and
concentrated. The residue was purified by flash chromatography on silica gel
using 2% ethyl acetate in heptane as eluent. Concentration of the appropriate
. .
CA 2760877 2017-03-20
Blakes Ref: 72571/00016
22995014.1
46
fractions afforded 1.40 g (90% yield) of the title compound as an oil. 1H-NMR
(300 MHz, CDCI3): ö 0.95.(t, 3H), 1.41 (d, 3H), 1.48 (s, 9H), 1.48-1.66 (in,
4H), 2.05 (m, 4H), 2.83 (m, 8H), 3.35 (in, 1H), 3.55 (m, 1H), 3.79 (q, 1H),
5.32-5.44 (m, 10H).
Example 7:
Preparation of 2-((5218Z,112,14Z,17Z)-icosa-5,8,11,14,17-
pentaertyloxy)propanoic acid:
.014
[0075] Trifluoroacetic acid (2 mL) was added to a solution of 2-
((5Z,8Z,1 1Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)propanoate (1.40 g,
3.36 mmol) in dichloromethane (10 mL) held under nitrogen and the reaction
mixture was stirred at room temperature for three hours. Diethyl ether (50
mL) was added and the organic phase was washed with water (30 mL), dried
(Na2SO4) and concentrated. The residue was subjected to flash
chromatography on silica gel using increasingly polar mixtures of heptane,
ethyl acetate and formic acid (95:5:0.25 80:20:1) as eluent. Concentration
of the appropriate fractions afforded 0.67 g of slightly impure product. This
material was dissolved in heptane (15 mL), washed three times with water (5
mL), dried (Na2SO4), filtered and concentrated to afford 0.50 g (41% yield) of
the title compound as an oil. 1H-NMR (300 MHz, CDCI3): 6 0.99 (t, 3H), 1.40-
1.48 (m, 5H), 1.67 (m, 2H), 2.09 (m, 2.80-2.60 (m, 8H), 3.53 (m, 2H),
4.01 (q, 1H), 5.31-5.47 (m, 1011); MS (electro spray): 359.2 [IA-Hr.
Example 8:
Preparation of tert-butyl 2-((5Z,8Z11Z,14Z,17Z)-loosa-5,8,11,14,17-
pentaenyloxy)-2-methylpropanoate:
0
. . . . .
CA 2760877 2017-03-20
=
Blakes Ref: 72571/00016
22995014.1
47
[0076] A mixture of (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-
pentaen-1-ol, (0.83 g, 3.14 mmol), tetrabutylammonium chloride (0.24 g, 0.85
mmol) and t-butyl a-bromo isobutyrate (3.50 g, 15.7 mmol) was dissolved in
toluene (15 mL) and placed under nitrogen. An aqueous solution of sodium
hydroxide (50%, 5 mL) was added slowly under vigorous stirring at room
temperature. The resulting mixture was heated to 60 C and stirred for six
hours. The mixture was cooled, added water and extracted three times with
ether. The combined organic extract was washed with brine, dried (Na2SO4),
filtered and concentrated. The residue was purified by flash chromatography
on silica gel using a gradient of 5-10% ethyl acetate in heptane as eluent
Concentration of the appropriate fractions afforded 0.60 g (44% yield) of the
title compound as an oil. MS (electro spray): 453.3 [M+Na]'.
Example 9:
Preparation of 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaeny1oxy)-
2-methylpropanoic acid:
OH
0
[0077] Trifluoroacetic acid (5 mL) was added to a solution of tert-
butyl 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)-2-
methylpropanoate (600 mg, 1.39 mmol) in dichloromethane (20 mL) under
nitrogen and the reaction mixture was stirred at room temperature for two
hours. Water was added and the aqueous phase was extracted twice with
dichloromethane. The combined organic extract was washed with brine, dried
(Na2SO4), filtered and concentrated. The residue was purified by flash
chromatography on silica gel using a mixture of heptane, ethyl acetate and
formic acid (80:20.1) as eluent. The appropriate fractions were concentrated
and the residue (135 mg) was purified further by flash chromatography on
silica gel using a gradient of 5-10% of a mixture of ethyl acetate and formic
acid (95:5) in heptane as eluent. Concentration of the appropriate fractions
afforded 80 mg slightly impure product This material was dissolved in
. .
CA 2760877 2017-03-20
- . .
Blakes Ref: 72571/00016
22995014.1
48
heptane (5 mL), washed twice with water (5 mL), dried (Na2SO4), filtered and
concentrated to afford 40 mg (8% yield) of the title compound as an oil. 1H-
NMR (300 MHz, CDCI3): 6 0 99 (t, 3H), 1.47 (s, 6H), 1.64 (m, 2H), 2.07 (m,
4I-1), 2.81-2.88 (m, 811), 3.46 (1, 2H), 5.29-5.44 (m, 101-I); MS (electro
spray):
373.3 (m-Hr
Example 10:
Preparation of 2-((3Z,6Z,9Z,12Z)-pentadeca-3,6,9,12-
tetraenyloxy)butanoic acid:
[0078] A mixture of (3Z,6Z,9Z,12Z)-pentadeca-3,6,9,12-tetraen-1-ol
(S. Flock, Acta Chemica Scandinavica, (1999) 53, 436-445) (0.22g. 1.00
mmol), tetrabutyl ammonium chloride (0.10 g, 0.33 mmol) and t-butyl 2-
bromobutyrate (1.11 g, 5.00 mmol) was dissolved in toluene (10 ml) and
placed under nitrogen. An aqueous solution of sodium hydroxide (50%, 4 ml)
was added slowly under vigorous stirring at room temperature. The resulting
mixture was heated to 50 C and stirred for two hours and then at ambient
temperature over night. After cooling to room temperature, water was added
and the aqueous phase was extracted three times with ether. The combined
organic extract was washed with water and brine, dried (Na2SO4), filtered and
concentrated. The residue was purified by flash chromatography on silica gel
using 5% ethyl acetate in heptane as eluent. Concentration of the appropriate
fractions afforded 0.30 g of the f-butyl ester as an oil. The residue was
dissolved in dichloromethane (10 mL) and placed under nitrogen.
Trifluoroacetic acid (2 mL) was added and the reaction mixture was stirred at
room temperature for one hour. Water was added and the aqueous phase
was extracted twice with dichloromethane. The combined organic extract was
washed with brine, dried (Na2S0.4), filtered and concentrated. The residue
was purified by flash chromatography on silica gel using a mixture of heptane,
_ .
CA 2760877 2017-03-20
=
Blakes Ref: 72571/00016
22995014.1
49
ethyl acetate and formic acid (80:20:1) as eluent. Concentration of the
appropriate fractions afforded 0.18 g (59% yield) of the desired product as an
oil. 111-NMR (300 MHz, CDCI3): b 0.90-1.05 (m, 8H), 1.75-1.90 (m, 2H). 2.05-
2.15 (m, 2H), 2.30-2.50 (m, 2H), 2.85 (m, 6H), 3.60 (m, 2H), 3.85 (t, 1H),
5.25-
5.60 (m, 8H).
Example 11:
Preparation of 2-((9Z,12Z,15Z)-octadeca-9,12,15-trienyloxy)butanoic
acid:
0 =
[0079] A mixture of (9Z,12Z,15Z)-octadeca-9,12,15-trien-1-ol (1.26
g, 4.76 mmol), tetra-butyl ammonium chloride (0.36 g, 1.28 mmol) and I-butyl
2-bromobutyrate (2.86 g, 12.82 mol) was dissolved in toluene (15 mL) and
placed under nitrogen. An aqueous solution of sodium hydroxide (50%, 6 ml)
was added slowly under vigorous stirring at room temperature. The resulting
mixture was heated to 60 C and stirred for five hours. After cooling to room
temperature, water was added and the aqueous phase was extracted three
times with ether. The combined organic extract was washed with water and
brine, dried (Na2SO4), filtered and concentrated. The residue was purified by
flash chromatography on silica gel using a gradient of 2.5-5% ethyl acetate in
heptane as eluent. Concentration of the appropriate fractions afforded. 1.36 g
of the t-butyl ester as an oil. The residue was dissolved in dichloromethane
(20 mL) and placed under nitrogen. Trifluoroacetic acid (5 mL) was added
and the reaction mixture was stirred at room temperature for one hour. Water
was added and the aqueous phase was extracted twice with dichloromethane.
The combined organic extract was washed with brine, dried (Na2SO4), filtered
and concentrated. The residue was purified by flash chromatography on silica
gel using a mixture of heptane, ethyl acetate and formic acid (80:20:1) as
eluent. Concentration of the appropriate fractions afforded 0.38 g (23% yield)
=
. .
CA 2760877 2017-03-20
Blakes Ref: 72571/00016
22995014.1
of the desired product as an oil. 1H-NMR (300 MHz, CDC13): 6 0.95-1.00 (m,
6H), 1.30-1.45 (m, 10H), 1.65 (m, 2H), 1.80 (m, 2H), 2.10 (m, 4H), 2.80 '(m,
4H), 3.50 (m, IH), 3.60 (m, I H), 3.85 (t, 1H), 5.30-5.50 (m, 6H); MS (electro
spray): 349.2 (M-H].
Example 12:
Preparation of tert-butyl 2-ethy1-24(5Z,8Z,11Z,14Z,17Z)-icosa-
5,8,11,14,17-pentaen-1-yloxy)butanoate:
o I
100801 terf-Butyl 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-
pentaen-1-yloxy)butanoate (480 mg, 1.11 mmol) was added dropwise over 30
minutes to a solution of lithium ditsopropylamine (LDA) (2.0 M, 750 pL, 1.50
mmol) in dry tetrahydrofuran (10 mL) held at -70 C under nitrogen. The
reaction mixture was stirred for 30 minutes. Ethyl iodide (312 mg, 2.00 mmol)
was added in one portion and the resulting mixture was warmed to ambient
temperature during 1 hour. The reaction mixture was stirred at ambient
temperature for 17 hours. The mixture was poured into saturated NH4C1 (aq.)
(50 mL) and extracted with heptane (2 x 50 mL). The combined organic
phases was washed succesively with brine (50 mL), 0.25 M HCI (50 mL) and
brine (50 mL), dried (MgSO4), filtered and concentrated. The residue was
purified by flash chromatography on silica gel using increasingly polar
mixtures of heptane and ethyl acetate (100:0 -) 95:5) as eluent.
Concentration of the appropriate fractions afforded 343 mg (67% yield) of the
title compound as an oil 1H NMIR (300 MHz, C0C13): 6 0.84 (t, 6H), 0.99 (td,
3H), 1.35-1.55 (m, 11H), 1.54-1.69(m, 2H), 1.68-1.87 (m, 4H), 1.99-2.24
(m, 4H), 2.74-2.99 (m, 8H), 3.31 (t, 2H), 5.23-5.52 (m, 10H); MS (electro
spray): 401.3 (M-1r
. . . .
CA 2760877 2017-03-20
Blakes Ref: 72571/00016
22995014.1
51
=
Example 13:
Preparation of 2-ethyl-2-((51,82,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-
-yloxy)butanoic acid:
c
[0081] A mixture of formic acid (5 ml) and tert-butyl 2-ethyl-2-
((5Z,8Z,11Z,14117Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)butanoate (250
mg, 0.55 mmol) was stirred vigorously under nitrogen at room temperature for
4.5 hours. The formic acid was removed in vacua. The residue was purified by
flash chromatography on silica gel using increasingly polar mixtures of
heptane and ethyl acetate (100:0 -> 80:20) as eluent. Concentration of the
appropriate fractions afforded 163 mg (74% yield) of the title compound as an
oil. 11--1NMR (300 MHz, CDCI3): 6 0.86 (t, 6H), 0.99(t, 3H), 1.36 - 1.57 (m,
2H), 1.68 (dd, 2H), 1.73- 1.98 (m, 4H), 2.11 (tt, 4H), 2.70- 3.01 (m, BH).
3.39 (t, 2H), 5.20- 5.56 (m, 10H). MS (electrospray): 481.4 [Mi-Na].
Example 14:
Preparation of tert-butyl 2-((4Z,7Z,10Z,131,16Z,19Z)-docosa-
4,7,10,13,16,19-hexaen-1-yloxy)propanoate:
0 \
[0082] An aqueous solution of sodium hydroxide (50 % (w/w), 6 ml)
was added portionwise to a mixture of (5Z,8Z,11Z,14Z,17Z)-icosa-
5,8,11,14,17-pentaen-1-ol (2.01 g, 6.39 mmol), ted-butyl-2-bromobutyrat (2.85
g, 12.8 mmol) and tetrabutylammonium bisulfate (0.65 g, 1.91 mmol) in
toluene (12 ml). The reaction mixture was vigorously stirred under N2-
atmosphere and warmed to 50 C. The reaction mixture was stirred at 50 C for
a total of 22 hrs. Additional tert-butyl-2-bromobutyrat (1.43 g, 6.39 mmol)
and
- -
CA 2760877 2017-03-20
Blakes Ref: 72571/00016
22995014.1
52
(1.44 g, 6.44 mmol) was added after 1 t,4 hrs and 3 hrs respectively. The
mixture was cooled and added ice-water (-50 ml) and heptane (50 ml), the
phases were separated and the organic phase was concentrated under
reduced pressure. Flash chromatography on silica gel (30 g) eluting with
heptane-heptane/Et0Ac (99:1) yielded 2.12 g of the title compound as a
liquid. 1H NMR (300 MHz, CDCI3) 5 0.94-1.04 (m, 6H). 1.47 (s, 9H), 1.68-1.85
(m, 411), 1.93-2.20 (m, 4H), 2.80-2.86 (m, 10H), 3.28-3.36 (m, 1H), 3.55-3.63
, (m, 2H), 5.27-5.43 (m, 12H)
Example 15:
Preparation of 2-((4Z,7Z,10Z,13Z,16Z,19Z)-clocosa-4,7,10,13,16,19-
hexaen-1-yloxy)butanoic acid:
cxx')/oK
=
[0083] A mixture of ferf-butyl 2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-
4,7,10,13,16,19-hexaen-1-yloxy)propanoate (2.09 g, 4.58 mmol) in HCOOH
(9 ml) was stirred at 40 C under N2-atmosphere for 6 hrs. The reaction
mixture was diluted with diethyl ether (100 mL), washed with water (30 ml),
dried (MgSO4), filtered and evaporated under reduced pressure. Dry-flash on
silica gel (50 g) eluting with toluene ¨ toluene (85:15) yielded 1.44 g of the
crude title compound. Flash chromatography on silica gel (30 g) eluting with
heptane ¨ heptane/(Et0Ac w15% HCCOH) 98:2-95:5-80:20 yielded 1.07 g
(58% yield) of the title compound as a liquid. 1H NMR (200 MHz, CDCI2)
0.97 (t, 3H), 0.99 (t, 311), 1.64-1.91 (m, 411), 2.00-2.23 (m, 411), 2.78-2.87
(m,
1011), 3.42-3.66 (m, 211), 3.85 (dd, 1H), 5.26-5.46 (m, 12H). MS
(electrospray)
(neg): 399 (M-Hi.
Example 16:
CA 2760877 2017-03-20
_
= Blakes Ref: 72571/00016
22995014.1
53
Preparation of tert-butyl 2-((3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-
pentaen-1-yloxy)butanoate:
¨ ¨
)1
\17
[0084] An aqueous solution of sodium hydroxide (50 A) (w/w), 6 mL)
was added portionwise to a mixture of (3Z,6Z,9Z,12Z,15Z)-octadeca-
3,6,9,12,15-pentaen-1-ol (1.66 g, 6.37 mmol), tert-buty1-2-bromobutyrat (2.86
g, 12.8 mmol) and tetrabutylammonium bisulfate (0.65 g, 1.91 mmol) in
toluene (12 ml). The reaction mixture was vigorously stirred under N2-
atmosphere and. warmed to 50 C. The reaction mixture was stirred at 50 C for
a total of 25 hrs. Additional tert-butyl-2-bromobutyrat (1.43 g, 6.41 mmol)
and
(1.42 g, 6.38 mmol) was added after 1 1/2 hrs and 3 his respectively. The
mixture was cooled to room temperature and added water (30 mL) and
heptane (50 mL), the 'resulting two phases were separated and the organic
phase was dried (Na2SO4), filtered and evaporated under reduced pressure.
Flash chromatography on Silica gel (30 g) eluting with heptane-
heptane/Et0Ac (99:1) yielded 1.55 g of the title compound as a liquid. 1H
NMR (300 MHz, CDCI3) 0.96 (t, 3H), 0.97 (t, 3H), 1.48 (s, 9H), 1.64-1.86 (m,
2H), 2.03-2.12 (m, 2H), 2.39 (dd, J = 12.1, 6.7 Hz, 2H), 2.79-2.86 (m, 8H),
3.29-3.37 (m, 1H), 3.57-3.66 (m, 2H), 5.27-5.49 (m, 10 H).
Example 17:
Preparation of 2-((3Z,6Z,9Z,12Z,15Z)-octadeca-3,6.9,12,15-pentaen-1-
yloxy)butanoic acid:
0
CA 2760877 2017-03-20
Blakes Ref: 72571/00016
22995014.1
= 54
(00851 A mixture of tert-butyl 24(3Z,6Z,9Z,12Z,15Z)-octadeca-
3,6,9,12,15-pentaen-1-yloxy)butanoate (2.09 g, 4.58 mmol) in HCOOH (9 mL)
was stirred at 40 C uncle:* N2-atmosphere for 6 hrs. The reaction mixture was
diluted with diethyl ether (100 mL), washed with water (30 mL), dried
(MgSO4), filtered and evaporated under reduced pressure. Dry-flash on silica
gel (50 g) eluting with toluene ¨ toluene/Et0Ac (85:15) yielded 1.44 g of the
= crude tile compound. Flash chromatography on silica gel (30 g) eluting
with
heptane ¨ heptane/(Et0Ac w/5 % HCCOH) 98:2-95:5-80:20 yielded 1.07 g
* (58% yield) of the title compound as a liquid. 1H NMR (200 MHz, CDCI3) 8
0.97 (t, 3)1), 0.99 (t, 3H), 1.75-1.91 (m, 2H), 2.00-2.15 (m, 2)1), 2.35-2.48
(m,
2H), 2.78-2.87 (m, 8H), 3.47-3.62 (m, 2H), 3.85 (dd, 111), 5.25-5.55 (m,
10)1).
MS (electrospray) (neg): 345 on-Hy.
Biolooical testinc
Example 18:
Evaluation of PPAR activation in vitro
(00861 The assays were carried out in vitro using mammalian-one-
hybrid assays (M1H) comprising GAL4-DNA binding domain-PPAR-LBD
fusion constructs in conjunction with 5xGAL4-sites driven Photinus pyre/Is
luciferase reporter constructs in transiently transfected HEK293 cells.
[00871 The cells were transfected 4-6h and grown overnight before
compounds were added. Compound incubation was 16-20h.
[00881 Renilla reniformis luciferase, driven by a constitutive
promoter, was included as internal control to improve experimental accuracy.
[0089] The compounds (A-C) and a positive control were tested at
six different concentrations in duplicate. The positive controls were GW7647
(PPARcc), GW501516 (PPAR8) and rosiglitazone (PPARy). The efficacy of
the controls were set to 100%.
=
_
CA 2760877 2017-03-20
Blakes Ref: 72571/00016
22995014.1
OH
A
[0090] The results are presented in Table 1.
Tablet PPAR activation in vitro.
= = PPARa PRAM PPARy
Compound ECso Efficacy EC so Efficacy ECso Efficacy
= Pos. ctr. 0.45 100% 0.33 nM 100%
22 nM 100%
nM
A 307 nM 82% inactive inactive 806 nM 22%
405 nM 86% inactive inactive 644 nM 27%
167 nM 54% inactive inactive 515 nM 25%
Example 19:
Evaluation of the effects .on in vivo lipid metabolism in a dyslipidemic
mouse model (APOE*3Leiden transgenic mice)
[0091] This animal model has proven to be representative of the
human situation with respect to plasma lipoprotein levels and its
responsiveness to hypolipidemic drugs, such as statins and fibrates, and
nutritional intervention. In addition, depending on the level of plasma
cholesterol, APOE*3Leiden mice develop atherosclerotic lesions in the aorta
resembling those found in humans with respect to cellular composition and
morphological and immunohistochemical characteristics.
[0092] Female APOE'3Leiden mice were put on a semi-synthetic
Western-type diet (WTD, 15% cocoa butter, 40% sucrose and 0.25%
cholesterol; all wfw). With this diet the plasma cholesterol level reached
mildly elevated levels of approximately 12-15 mmolil. After a 4 week run-in
period the mice were sub-divided into groups of 10 mice each, matched for
plasma cholesterol, triglycerides and body weight (tr-0).
. .
. .
CA 2760877 2017-03-20
- = "
Blakes Ref: 72571/00016
22995014.1
56
[0093) The test substances were administered orally as admix to the
Western-type diet. To facilitate the mixing of the compounds sunflower oil
was added to a total oil volume of 10 mL/kg diet.
[0094] At t = 0 and 4 weeks blood samples were taken after a 4
hour-fast to measure plasma cholesterol and triglycerides.
[0095] The test substance (A) was tested at 0.3 mmol/kg bw/day.
The reference (Omega-3 acid ethyl esters, OmacorTM, Lovazaw) was tested
at 3.3 mmol/kg bw/day.
[0098] The results are shown in tgure 1.
Example 20:
Evaluation of the effects on in vivo lipid metabolism in a dyslipidemic
mouse model (APOE*3Leiden.CETP transgenic mice)
[0097] The APOE*3Leiden.CETP transgenic mouse is a model
where the human cholesterol ester transfer protein has been introduced to the
APOE*3Leiden transgenic mouse. This results in a more human-like
lipoprotein profile. This model is very well suited for testing the effects of
drugs on plasma HDL and triglyceride levels.
[0098] Female APOE*3Leiden.CETP mice were put on a semi-
synthetic modified Western-type diet (0.15% cholesterol and 15% saturated
fat, all w/w). With this diet the plasma cholesterol level reaches moderately
elevated levels of about 13-15 mmo1/1 and triglyceride levels of approximately
3 mmo1/1. After a 4 week run-in period the mice were sub-divided into groups
of 6 mice each, matched primarily for plasma cholesterol, triglycerides and
body weight and secondarily for HDL-cholesterol (t=0).
[0099] The test substances were administered orally as admix to the
Western-type diet.
[00100] At t 0 and 4 weeks blood samples were taken after a 4
hour-fast to measure plasma cholesterol, HDL-cholesterol and triglycerides.
. . . . . . . . . . .
CA 2760877 2017-03-20
Blakes Ref. 72571/00016
22995014.1
57
[00101] The test substance (A) was tested at 0.18 mmoVkg bw/day.
The reference (Fenofibrate) was tested at 10 mg/kg bw/day.
[001021 The results are shown in figures 2 and 3.
Example 21:
Evaluation of the effects on in vivo atherosclerosis development in a
mouse model (APOE*3Leiden.CETP transgenic mice)
(00103) This animal model has proven to be representative of the
human situation with respect to plasma lipoprotein levels and its
responsiveness to hypolipidemic drugs (like statins, fibrates etc.) and
nutritional intervention. APOE*3Leiden.CETP mice develop atherosclerotic
lesions in the aorta resembling those found in humans with respect to cellular
composition and morphological and immunohistochemical characteristics.
[001041 Female APOE*3Leiden.CETP mice were put on a Western-
type diet (WTD) with 0.15% cholesterol and 15% saturated fat; resulting in
plasma cholesterol levels of about 13-15 mM. After a 3 week run-in period on
the WTD, the mice were sub-divided into 4 groups of 15 mice, control (no
treatment), compound A, fenofibrate and a low-cholesterol diet. The groups
were matched for body weight, plasma total cholesterol (TC), HDL cholesterol
(lDL-C) and trielycerides (TG) after 4h fasting (t=0).
[00105] The test substances were administered orally as admix to the
Western-type diet To facilitate the mixing of the compounds sunflower oil
was added to a total oil volume of 10 mIJkg diet. The test compound (A) was
tested at initially at 0.1 mmol/kg bw/day and reduced to 0.04 mmol/kg bw/day
at 4 weeks. The initial dose was based on a prior dose-finding study to
establish the required dosage that would reduce VLDULDL cholesterol by 25-
30%.
[00106] The dosage of fenofibrate was initially 10 mg/kg bw/day and
was reduced to 4,2 mg/kg bw/day (to parallel reductions in VLDULDL induced
by compound A).
= = = =
CA 2760877 2017-03-20
Blakes Ref: 72571/00016
22995014.1
58
[00107] At t = 0, 4. 8, 12 and 14 weeks blood samples were taken
after a 4 hour-fast to measure food intake, total plasma cholesterol, HDL
cholesterol and triglycerides and lipoprotein profiles. Atherosclerosis
development in the aortic root (lesion number, total lesion area and lesion
severity) was assessed at study-end.
[00108] The invention shall not be limited to the shown embodiments
and examples.
CA 2760877 2017-03-20
